RHOJ controls EMT-associated resistance to chemotherapy

DOI HANDLE HANDLE HANDLE PDF ほか2件をすべて表示 一部だけ表示 被引用文献3件 参考文献64件 オープンアクセス

書誌事項

公開日
2023-03-22
資源種別
journal article
権利情報
  • https://creativecommons.org/licenses/by/4.0
  • https://creativecommons.org/licenses/by/4.0
DOI
  • 10.1038/s41586-023-05838-7
公開者
Springer Science and Business Media LLC

この論文をさがす

説明

<jats:title>Abstract</jats:title> <jats:p> The resistance of cancer cells to therapy is responsible for the death of most patients with cancer <jats:sup>1</jats:sup> . Epithelial-to-mesenchymal transition (EMT) has been associated with resistance to therapy in different cancer cells <jats:sup>2,3</jats:sup> . However, the mechanisms by which EMT mediates resistance to therapy remain poorly understood. Here, using a mouse model of skin squamous cell carcinoma undergoing spontaneous EMT during tumorigenesis, we found that EMT tumour cells are highly resistant to a wide range of anti-cancer therapies both in vivo and in vitro. Using gain and loss of function studies in vitro and in vivo, we found that RHOJ—a small GTPase that is preferentially expressed in EMT cancer cells—controls resistance to therapy. Using genome-wide transcriptomic and proteomic profiling, we found that RHOJ regulates EMT-associated resistance to chemotherapy by enhancing the response to replicative stress and activating the DNA-damage response, enabling tumour cells to rapidly repair DNA lesions induced by chemotherapy. RHOJ interacts with proteins that regulate nuclear actin, and inhibition of actin polymerization sensitizes EMT tumour cells to chemotherapy-induced cell death in a RHOJ-dependent manner. Together, our study uncovers the role and the mechanisms through which RHOJ acts as a key regulator of EMT-associated resistance to chemotherapy. </jats:p>

収録刊行物

  • Nature

    Nature 616 (7955), 168-175, 2023-03-22

    Springer Science and Business Media LLC

被引用文献 (3)*注記

もっと見る

参考文献 (64)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

問題の指摘

ページトップへ